How effective is Mavenclad for MS?

Drugs.com

Official answer

by Drugs.com

In March 2019, the FDA approved Mavenclad (cladribine), a purine antimetabolite used for the treatment of relapsing forms of multiple sclerosis (MS) in adults 18 years of age and older. Mavenclad is used in relapsing-remitting disease (RRMS) and active secondary progressive disease (SPMS). Mavenclad is not recommended for MS patients with clinically isolated syndrome or as a first-line agent due to its safety profile.

  • Mavenclad was studied in CLARITY, a Phase 3, double-blind study and compared to a placebo (treatment with no active drug).
  • The effectiveness of Mavenclad was shown in a 96 week (~2 year) clinical trial with 1,326 patients with relapsing forms of MS who had at least one relapse in the previous 12 months.
  • In the study, Mavenclad significantly decreased the number of relapses (the primary endpoint of the study) when compared to a placebo (an inactive treatment). Over the 96 weeks, 81% of patients who took Mavenclad were relapse-free compared to 63% of those who took a placebo.
  • Mavenclad also decreased 3-month progression of disability due to MS, measured by expanded disability status scale (EDSS), when compared to placebo. Results showed 87% of patients on Mavenclad had no confirmed EDSS progression compared to 81% of patients taking a placebo, a 33% risk reduction.
  • Mavenclad helps to reduce immune system cells (T and B cells) that can attack nerves and lead to inflammation in MS. The number of these cells will begin to recover after each yearly Mavenclad administration. This may take several months and your levels of immune system cells may not go back to pretreatment levels.

    Related medical questions

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords

    AI Assitant